Based on our Pharmacor advisory service entitled
Venous Thromboembolism, Decision Resources is offering an exclusive analyst call entitled
Landmark Findings from the European Society of Cardiology Congress - Assessing Xarelto’s Potential to Streamline the Treatment of VTE. Because this presentation will feature major updates, it is
ONLY available to purchasers of this Pharmacor advisory service.
Recorded Live Friday, September 10, 2010
This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., answers the following questions:
- How do the recent Xarelto findings compare with results from Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) RE-COVER trial?
- What other novel oral anticoagulants are most likely to compete with Xarelto for the treatment of VTE?
- What are the current opinions of thought leaders regarding the use of novel oral anticoagulants for VTE treatment?
Contact us to learn how you can purchase this service and attend.
Click here to view the invite.